SecBot SecBot
SECBOTREPLAY Home › Report › PLX

PLX · Protalix reported Q2 2026 revenue of $19.9M, beating the $12.9M…

Protalix BioTherapeutics, Inc. · 8-K filed Aug 12, 2026 at 06:59 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Aug 12, 2026 at 06:59 ET

Protalix reported Q2 2026 revenue of $19.9M, beating the $12.9M consensus, and EPS of $0.05, beating the $-0.01 consensus. Revenue growth was driven by higher Elfabrio sales to Chiesi and Fiocruz, partially offset by lower Pfizer purchases. The company reiterated full-year 2026 revenue guidance of $78M-$83M.

  • Q2 2026 total revenue of $19.9M, up from $15.7M in Q2 2025
  • Q2 2026 net income of $3.8M ($0.05 per share) vs net income of $164K ($0.00) in Q2 2025
  • Revenues from selling goods were $19.8M in Q2 2026, up $4.4M from Q2 2025, driven by higher Elfabrio sales to Chiesi and Fiocruz
  • Revenues from license and R&D services were $68K in Q2 2026 vs $218K in Q2 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access